Drug Profile
Recombinant interleukin-2 - Amoytop Biotech/BioGeneric Pharma
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Amoytop Biotech; BioGeneric Pharma
- Developer Amoytop Biotech
- Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants; Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Unspecified in China
- 06 Jan 2016 Clinical trials in Undefined indication in China (unspecified route)